Request Demo
Last update 24 Oct 2026
SHR-A1912
Last update 24 Oct 2026
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms SHR A1912, SHR-A1912, SHRA1912 |
Target |
Action inhibitors |
Mechanism CD79B inhibitors(B-cell antigen receptor complex-associated protein beta chain inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (United States) |
Login to view timeline
Structure/Sequence
Molecular FormulaC25H31N5O8 |
InChIKeyDWPLKZYCOGLRPC-SFHVURJKSA-N |
CAS Registry2413428-36-9 |
Boost your research with our ADC technology data.
login
or
Related
3
Clinical Trials associated with SHR-A1912NCT06929624
A Phase 3, Open-label, Randomized Study of SHR-A1912 Combined With Rituximab + Gemcitabine + Oxaliplatin (R-GEMOX) Versus R-GEMOX in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT06104553
A Phase Ib/II Study of SHR-A1912 Combined With Other Therapies in Patients With B-cell Non-Hodgkin 's Lymphoma
NCT05113069
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1912 for Injection as Monotherapy in Patients With B-cell Lymphoma
100 Clinical Results associated with SHR-A1912
Login to view more data
100 Translational Medicine associated with SHR-A1912
Login to view more data
100 Patents (Medical) associated with SHR-A1912
Login to view more data
100 Deals associated with SHR-A1912
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | Phase 3 | China | 24 Apr 2025 | |
| Diffuse large B-cell lymphoma recurrent | Phase 3 | China | 24 Apr 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 41 | SHR-A1912 + R-GemOx | bblzovhsnh(zlhvxakooj) = usaylvhtkl scqrxiaeoq (eghbkxpvrw, 55.9 - 86.2) View more | Positive | 30 May 2025 | ||
Phase 1 | 49 | utyxrapmky(yxojnkycyj) = apuvvahube vuqkjeltxw (uqcjmkznjv, 39.8 - 71.5) | Positive | 24 May 2024 | |||
utyxrapmky(yxojnkycyj) = hfdalfkdgq vuqkjeltxw (uqcjmkznjv, 39.8 - 71.5) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free